Clinical trials: Thrombin
Blood Component Transfusion
Appropriateness of Frozen Plasma Use in Canada
There is little evidence to guide the current use of Frozen Plasma. Despite this, over 260,000 units of frozen plasma are transfused in Canada annually.
- Trial name
- NCT01187030
- Volunteers
- 2,580 people
- Sponsor
- Ottawa Hospital Research Institute
Congenital Disorders of Glycosylation
Study of Hemostasis in Patients With Congenital Disorder of Glycosylation
The purpose of this study is to investigate the coagulation balance in a cohort of congenital disorder of glycosylation (CDG) patients using conventional tests combined with an integrated approach of their coagulation disorders…
- Trial name
- CDG-Coag (NCT03560570)
- Testing
- Coagulation assay, Clinical data collection
- Where
- France
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bleeding Disorder
Bleeding of Unknown Cause: a Swiss Case-control Study
The goal of this prospective cohort is to identified specific biological patterns in patients with a bleeding of unknown cause and to study the specific mechanisms of the bleeding disorder for each subset of patients.
- Trial name
- SWISS-BUC (NCT05713734)
- Testing
- Thrombin generation, Fibrinolysis, Fibrin clot structure
- Where
- 7 sites in Switzerland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Recurrent Miscarriage
The Role of Prothrombin Gene and Methylenetetrahydrofolate Reductase(MTHFR) Gene Polymorphisms as Risk Factors for Recurrent Miscarriage
Recurrent miscarriage is a pregnancy loss before 20 weeks of gestation. The recurrent pregnancy loss(RPL) usually occurring in the first trimester of gestation and its rate is quite high (15-20% even in full reproductive period)…
- Trial name
- NCT03209063
- Testing
- polymerase chain reaction
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- Assiut University
HCC, Cirrhosis, Liver
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)
The objective of this observational study is to evaluate the clinical utility of the combined assay of 3 biomarkers: α-FP, α-FP-L3 and DCP (simultaneously measured by µTASWakoTM i30 automated in vitro diagnostic system) in…
- Conditions
- HCC, Cirrhosis, Liver, NAFLD, HBV
- Trial name
- GALAD (NCT05781568)
- Testing
- Biomarker dosage
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Aortic Coarctation
A Pilot Study of Thrombin Generation Changes in Neonates Undergoing Placement of a Blalock-Taussig Shunt
The primary goal of this investigation is to describe perioperative thrombin generation in neonates undergoing placement of a Blalock-Taussig (BT) shunt to better understand the coagulation changes that precipitate postoperative…
- Trial name
- NCT01340378
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Severe Hemophilia A With Inhibitor
Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors
This is an observational, prospective, longitudinal, multicenter, cohort study designed with the scope to verify whether or not TGA may predict effectiveness of different FVIII concentrates class (devoid or rich of VWF) in…
- Trial name
- PredicTGA (NCT01505946)
- Testing
- TGA (Thrombin generation Assay)
- Where
- 15 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Grifols Italia S.p.A
Beta Thalassemia Major Anemia
Thrombin Generation in Beta-thalassemia Major
This study aims to evaluate the persistence of a hypercoagulable state in chronically-transfused patients with beta thalassemia major, by using the thrombin generation test (performed in whole blood and plasma).
- Trial name
- TG-THAL (NCT04962984)
- Testing
- blood sampling
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Cardiopulmonary Bypass
Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass
The primary goal of this investigation is to determine the ability of recombinant activated factor VII (rFVIIa) and prothrombin complex concentrate (PCC) to improve thrombin generation in neonatal plasma after CPB.
- Trial name
- NCT01352143
- Testing
- Recombinant activated factor VII, Prothrombin Complex Concentrate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Unexplained Isolated Provoked Hemorrhages, Familial Bleeding Disorder
Markers of Defective Membrane Remodelling in Scott-like Syndromes
Purpose: Identification of the gene(s) involved in plasma membrane remodelling. Identification of the circulating markers affected by the defective membrane remodelling in a collection of families with unexplained provoked…
- Conditions
- Unexplained Isolated Provoked Hemorrhages, Familial Bleeding Disorder, Scott Syndrome
- Trial name
- NCT00617721
- Testing
- Blood withdrawal
- Where
- 5 sites in France, Martinique
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Detection and Genotyping of Factor V and Factor II Point Mutations
Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNA
As an external validation test of the performance of the VeraCode Genotyping Test for Factor V and Factor II on the BeadXpress System, clinical trials will be conducted at three sites.
- Trial name
- NCT00959504
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Illumina, Inc.
Rare Bleeding Disorders
Rare Bleeding Disorders in the Netherlands
Rationale: Rare bleeding disorders (deficiency of fibrinogen, factor II, V, V\&VIII, VII, X, XI, XIII, α2-antiplasmin or plasminogen activator inhibitor 1) are not well defined with respect to their clinical phenotype, laboratory…
- Trial name
- RBIN (NCT03347591)
- Testing
- WES, Several assays
- Where
- 7 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- Radboud University Medical Center
Bleeding, Cardiac Defect
ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery
In pediatric patients (newborns and infants weighing less than 10 kg) undergoing cardiac surgery with extracorporeal circulation postoperative bleeding represents a known complication with a significant impact on outcome.
- Conditions
- Bleeding, Cardiac Defect, Surgery--Complications, Fibrinogenopenia; Acquired
- Trial name
- ZEPLAST-PED (NCT04434001)
- Testing
- Fibrinogen Concentrate Human, Prothrombin Complex Concentrate, Fresh Frozen Plasma
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Policlinico S. Donato
ATIII Deficiency
Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery
The purpose of this study is to test whether the administration of ATIII during the intra-operative period results in improved anticoagulation for cardiopulmonary bypass (CPB) and an attenuation of the activation of the…
- Trial name
- NCT02103114
- Testing
- Anti-thrombin III
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Duke University
Surgical Bleeding
Topical Raplixa for Surgical Bleeding in Children
The purpose of the study is to determine if Raplixa plus Gelfoam is better than Gelfoam alone in stopping mild to moderate bleeding in children having surgery.
- Trial name
- NCT02117349
- Testing
- Raplixa, Gelfoam, Rescue treatment
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mallinckrodt
Thrombosis
Study Of Angiomax In Infants Under Six Months With Thrombosis
The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2.
- Trial name
- NCT00043277
- Testing
- Angiomax (bivalirudin)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The Medicines Company
Hemophilia
In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
Studies have shown, in haemophilia patients, the effectiveness of Anti TFPI antibody (aTFPIAb) to prevent joint and muscular bleeding (tissues poor in Tissue Factor (TF)).
- Trial name
- NCT05617209
- Testing
- thrombin generation measurement
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Extracorporeal Circulation; Complications, Extracorporeal Membrane Oxygenation Complication
DIC Markers and Thrombin Generation Parameters in Patients on ECMO Support: a Pilot Study
To study the correlation between novel DIC markers and thrombin generation parameters with thrombotic and hemorrhagic complications of patients on ECMO support.
- Trial name
- DIC-ECMO (NCT06095518)
- Testing
- DIC markers and Thrombin Generation Parameters
- Where
- Hong Kong
- Volunteers
- 49 people
- Sponsor
- Queen Mary Hospital, Hong Kong
Venous Thromboembolism
Thrombosis Outcomes in Pediatric Venous Thromboembolism
'The TOP Study' is a prospective cohort study whose main objective is to develop better prognostic biomarkers and identify children at risk of adverse thrombotic outcomes very early in the course after an initial venous…
- Trial name
- TOP (NCT03068923)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center
Traumatic Injury
Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have…
- Trial name
- NCT05568888
- Testing
- BE1116
- Where
- 113 sites in United States, Australia and 1 more
- Volunteers
- 1,366 people
- Sponsor
- CSL Behring